Philipps-Universitaet Marburg
- Address
- lock Available on a paid plan
Eye Diseases Research
The clinic focuses on eye diseases, investigating conditions such as macular edema due to central retinal vein occlusion and moderate-to-severe thyroid eye disease, with the goal of refining treatment protocols and reducing injection burden.
- Ranibizumab injection optimization
- Peripheral laser photocoagulation adjunct
- Satralizumab efficacy in thyroid eye disease
Collaboration with Philipps-Universitaet Marburg enables multidisciplinary expertise and patient‑centered outcomes.
Hematologic & Lymphatic Oncology
Research in hematologic and lymphatic diseases targets acute myeloid leukemia, early‑stage unfavorable classical Hodgkin lymphoma, large B‑cell lymphoma, and MSI‑high colorectal cancer, aiming to improve survival through innovative cellular and immunotherapies.
- CAR T cell therapy evaluation
- Checkpoint inhibitor strategies
- Lymphodepletion regimen optimization
With 50 investigators, the site advances precision oncology across multiple cancer types.
Immune‑Mediated Disorders
The department studies immune system diseases such as thyroid eye disease, employing novel biologics like satralizumab to assess efficacy and safety while seeking to lessen disease‑related disability.
- Subcutaneous immunotherapy trials
- Proptosis response assessment
- Safety profiling of new biologics
As an educational institution, the site integrates clinical insight with academic research.
Prostate Cancer Studies
Investigations into prostate cancer focus on metastatic hormone‑sensitive disease, comparing docetaxel dosing schedules and combining chemotherapy with darolutamide plus androgen deprivation therapy to enhance progression‑free survival.
- Docetaxel dosing comparisons
- Combination with androgen deprivation therapy
- Adverse event monitoring strategies
Commercial partnerships support the development of optimized therapeutic regimens.
Solid Tumor Investigations
The site addresses neoplasms including metastatic colorectal cancer, advanced HER2‑negative breast cancer, and melanoma, evaluating checkpoint inhibitors and combination regimens to extend overall survival and understand resistance patterns.
- Subcutaneous nivolumab/relatlimab study
- Combination immunotherapy trials
- Molecular resistance analysis in breast cancer
A total of 11 clinical trials contribute to a comprehensive oncology portfolio.
Neurology Trials
Efforts in nervous system diseases concentrate on refractory status epilepticus, testing adjunctive IV ganaxolone added to standard antiepileptic drugs to improve seizure control and patient safety.
- Adjunctive ganaxolone efficacy study
- Safety assessment in acute seizures
- Integration with standard of care protocols
The program aims to deliver faster, more effective interventions for life‑threatening seizures.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 229 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 218 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 44 by active trials.
- 1AstraZeneca AB6active
lock +43 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Philipps-Universitaet Marburg
lock Showing 1 of 119 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus | Marinus Pharmaceuticals Inc. | Phase III | Not Recruiting | Nov 2023 | Apr 2024 |
IMP list
lock Showing 1 of 229 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 8 | Unknown | 2019-08-26 | 2026-07-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.